Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01627782 · ClinicalTrials.gov registry record · Phase 2
A Study of Ketamine in Patients With Treatment-resistant Depression
A Phase 2 study of Major Depressive Disorder, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
- 13
- Study locations
NCT01627782: Completed Phase 2 study of Major Depressive Disorder, sponsored by Janssen Research & Development.
NCT01627782 is a Phase 2 study of Major Depressive Disorder that has completed, run by Janssen Research & Development. The registered enrollment target is 68 participants, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (82% lower). The trial reports 13 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01627782, a Phase 2 study of Major Depressive Disorder, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
- 13
- Study locations
Study Summary
The purpose of this study is to explore the optimal dose frequency of ketamine in patients with treatment-resistant depression (TRD).
Primary Outcome
The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60. Higher scores represent a more severe condition.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ketamine
Study Locations (13)
Connecticut
- - Hartford
- - New Haven
Alabama
- - Birmingham
Arkansas
- - Little Rock
Colorado
- - Centennial
Georgia
- - Atlanta
Maryland
- - Rockville
New Jersey
- - Marlton
New York
- - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2012-08-06 |
| Est. Completion | 2013-09-12 |
| Phase | Phase 2 |
What the finished NCT01627782 record still lists
NCT01627782 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01627782 lists 13 locations in 12 states (Connecticut, Alabama, Arkansas).
Frequently Asked Questions
What is clinical trial NCT01627782 about?
NCT01627782 is a clinical study titled "A Study of Ketamine in Patients With Treatment-resistant Depression". The purpose of this study is to explore the optimal dose frequency of ketamine in patients with treatment-resistant depression (TRD).
What is the current status of trial NCT01627782?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2012-08-06. Estimated completion is 2013-09-12.
What conditions does trial NCT01627782 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT01627782?
The interventions under investigation include: Placebo (DRUG), Ketamine (DRUG).
Who is sponsoring clinical trial NCT01627782?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01627782 being conducted?
This trial has 13 study locations across Alabama, Arkansas, Colorado, Connecticut, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01627782's enrollment target sits among peer trials
68 161st of 282 higher than 122 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
RECRUITING · Phase 2
-
Study of ALTO-300 in MDD
RECRUITING · Phase 2
-
Regulation of Affect and Physiology in Depression
RECRUITING · Phase 2
-
Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
RECRUITING · Phase 2
-
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI